GlassScriptPhysician profile
Gamil L Makar
NPI 1972544815
$81,713.79
in general payments reported to CMS, 2019-2025
85 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $8,598 · 2021: $16K · 2022: $17K · 2023: $5,573 · 2024: $4,729 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $12K · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,350.00 |
| Food and Beverage | $11,551.14 |
| Education | $156.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $58,798.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,145.47 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Merz North America, INC. | $1,750.68 | 2022-2024 | |
| Glaxosmithkline, LLC. | $1,680.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,190.29 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $1,185.98 | 2021-2025 | |
| Novo Nordisk INC | $969.92 | 2019-2025 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $898.94 | 2022-2025 | Sunosi, Symbravo, Auvelity |
| Merck Sharp & Dohme LLC | $872.47 | 2019-2025 | Verquvo, Steglatro, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $816.19 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $685.38 | 2019-2025 | Jardiance |
| Pfizer INC. | $658.39 | 2019-2025 | |
| Intra-Sana Laboratories | $586.57 | 2024-2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Lilly USA, LLC | $574.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sunovion Pharmaceuticals INC. | $418.95 | 2019-2022 |
Show all 85 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gamil Makar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.